MedPath

Adaptive Family Treatment for Adolescent Anorexia Nervosa

Not Applicable
Completed
Conditions
Anorexia Nervosa
Registration Number
NCT01579682
Lead Sponsor
Stanford University
Brief Summary

Anorexia Nervosa (AN) has the highest mortality rate compared to any other psychiatric disorder. The most promising treatment for adolescents with AN is family-based treatment (FBT). However, only 50% of patients receiving FBT fully remit at 12-month follow-up. Consequently, providing an alternative therapy early in the treatment course for those not responding to FBT may enhance overall outcome. This study aims to develop a new treatment - Intensive Family-Focused Treatment (IFT) - to improve outcomes in those adolescents, aged 12-18 years, who do not show an early response to FBT.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
90
Inclusion Criteria
  • Meets DSM-IV criteria for anorexia nervosa
  • Lives with at least one English-speaking parent who is willing to participate
  • Medically Stable
  • Adequate transportation to clinic
  • Proficient at speaking, reading, and writing English
Exclusion Criteria
  • Previous FBT for AN
  • Medical condition that may affect eating or weight

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Full remission from AN (%MBW>95)End of Treatment (6 months)

Weight restoration to at least 95% of Median body weight (calculated by height, weight, gender, and age)

Secondary Outcome Measures
NameTimeMethod
Changes in subscale scores of the EDEEnd of Treatment (6 months)

Eating Disorder Examination subscale measures (weight concern, shape concern, dietary restraint) within 1 standard deviation of normative scores.

Trial Locations

Locations (2)

Stanford University

🇺🇸

Stanford, California, United States

University of Chicago

🇺🇸

Chicago, Illinois, United States

Stanford University
🇺🇸Stanford, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.